CN101060840A - 核糖－半胱氨酸通过提高细胞内谷胱甘肽的送递和atp的水平以治疗缺氧的用途 - Google Patents

核糖－半胱氨酸通过提高细胞内谷胱甘肽的送递和atp的水平以治疗缺氧的用途 Download PDF

Info

Publication number
CN101060840A
CN101060840A CNA2005800393226A CN200580039322A CN101060840A CN 101060840 A CN101060840 A CN 101060840A CN A2005800393226 A CNA2005800393226 A CN A2005800393226A CN 200580039322 A CN200580039322 A CN 200580039322A CN 101060840 A CN101060840 A CN 101060840A
Authority
CN
China
Prior art keywords
ribcys
hypoxia
gsh
cysteine
ribose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800393226A
Other languages
English (en)
Chinese (zh)
Inventor
H·T·纳盖萨瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max International Ltd
Sal Jerve Te Ltd
Original Assignee
Bioceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioceuticals Inc filed Critical Bioceuticals Inc
Publication of CN101060840A publication Critical patent/CN101060840A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CNA2005800393226A 2004-11-17 2005-11-16 核糖－半胱氨酸通过提高细胞内谷胱甘肽的送递和atp的水平以治疗缺氧的用途 Pending CN101060840A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,933 2004-11-17
US10/990,933 US20060105972A1 (en) 2004-11-17 2004-11-17 Method to enhance delivery of glutathione and ATP levels in cells

Publications (1)

Publication Number Publication Date
CN101060840A true CN101060840A (zh) 2007-10-24

Family

ID=35759146

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800393226A Pending CN101060840A (zh) 2004-11-17 2005-11-16 核糖－半胱氨酸通过提高细胞内谷胱甘肽的送递和atp的水平以治疗缺氧的用途

Country Status (14)

Country Link
US (4) US20060105972A1 (https=)
EP (1) EP1824481B1 (https=)
JP (1) JP2008520681A (https=)
KR (1) KR20070095900A (https=)
CN (1) CN101060840A (https=)
AU (1) AU2005307885B2 (https=)
BR (1) BRPI0516814A (https=)
CA (1) CA2587616C (https=)
DK (1) DK1824481T3 (https=)
EA (1) EA014076B1 (https=)
ES (1) ES2390228T3 (https=)
MX (1) MX2007005835A (https=)
PL (1) PL1824481T3 (https=)
WO (1) WO2006055597A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105972A1 (en) 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
JP4982755B2 (ja) * 2006-06-27 2012-07-25 国立大学法人 長崎大学 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法
US8685951B2 (en) * 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
EP2413942A1 (en) * 2008-04-02 2012-02-08 Bioenergy Inc. Use of ribose in first response to acute myocardial infarction
TW201202209A (en) * 2010-01-28 2012-01-16 Max International Llc Methods of preparing thiazolidines
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
US20110287109A1 (en) * 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products
CA2843388A1 (en) * 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
JP7137745B2 (ja) * 2015-05-22 2022-09-15 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼインａ２および抗酸化能
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4736060A (en) 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
JPS63152325A (ja) * 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
WO1992018120A1 (en) * 1991-04-15 1992-10-29 Teijin Limited Preventive or remedy for ischemia, reperfusion-induced tissue disorder and arrhythmia as well as pulmonary disorder caused by activated oxygen free radical
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
JP2001511153A (ja) 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
US6730336B2 (en) 1998-01-30 2004-05-04 The Procter & Gamble Co. Fortified beverages with improved texture and flavor impact at lower dosage of solids
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US7153503B1 (en) 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
US6534480B2 (en) * 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6881425B2 (en) 2001-08-31 2005-04-19 Council Of Scientific And Industrial Research Custom made herbal health promotive formulation for females/expectant mothers
US6572899B1 (en) 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US7455857B2 (en) 2003-04-08 2008-11-25 Janeel Henderson Energy generating composition
GB0319463D0 (en) 2003-08-20 2003-09-17 Givaudan Sa Compounds
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20060105972A1 (en) 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
US8962058B2 (en) 2005-11-23 2015-02-24 The Coca-Cola Company High-potency sweetener composition with antioxidant and compositions sweetened therewith
WO2007094827A2 (en) 2006-02-10 2007-08-23 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
US20100074969A1 (en) 2008-09-19 2010-03-25 Unicity International, Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
TW201201712A (en) 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
US20110287109A1 (en) 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products

Also Published As

Publication number Publication date
EA014076B1 (ru) 2010-08-30
US20060105972A1 (en) 2006-05-18
MX2007005835A (es) 2007-10-08
US20130317072A1 (en) 2013-11-28
JP2008520681A (ja) 2008-06-19
AU2005307885A1 (en) 2006-05-26
WO2006055597A1 (en) 2006-05-26
DK1824481T3 (da) 2012-09-24
ES2390228T3 (es) 2012-11-07
PL1824481T3 (pl) 2012-11-30
CA2587616C (en) 2015-03-17
US8501700B2 (en) 2013-08-06
US20090042822A1 (en) 2009-02-12
EP1824481A1 (en) 2007-08-29
EA200701017A1 (ru) 2007-10-26
AU2005307885A2 (en) 2006-05-26
EP1824481B1 (en) 2012-08-29
AU2005307885B2 (en) 2010-12-23
KR20070095900A (ko) 2007-10-01
BRPI0516814A (pt) 2008-09-23
US20160082029A1 (en) 2016-03-24
US9144570B2 (en) 2015-09-29
CA2587616A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
US9144570B2 (en) Method to enhance delivery of glutathione and ATP levels in cells
US6030950A (en) Pharmaceutical therapeutic use of glutathione derivative
O'Connell et al. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide
FI97891C (fi) Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi
TWI584805B (zh) Prevention and treatment of influenza virus infectious diseases
Miquel et al. Aging and increased oxidation of the sulfur pool
US5248697A (en) Enhancement of glutathione levels with glutamine
EP3281629A1 (en) Prophylactic/therapeutic agent for virus infections which comprises ala compound
CN106659701A (zh) 用于治疗年龄相关性症状和疾病的酮基丁酸酯化合物和组合物
US11253495B2 (en) Pharmaceutical composition for treating excessive lactate production and acidemia
US20050187271A1 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or its physiologically tolerable salts as a cancer-fighting agent
CN104415023A (zh) 预防或/和治疗胰岛素抵抗及相关病症的组合物
US20060004096A1 (en) Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
HK1114501A (en) Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells
JP2873089B2 (ja) 虚血・再灌流組織障害及び不整脈並びに活性酸素・フリーラジカルによる肺障害の予防又は治療剤
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
Grishina et al. Accelerated utilization of lactate under the effect of hypoxen after intensive exercise
US20060258754A1 (en) Method of treating endothelial dysfunction, oxidative stress and related diseases
US9295660B2 (en) Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
UA120027U (uk) Спосіб корекції порушеного за умов алоксанового діабету стану глутатіонової системи у яснах
MXPA98009259A (en) Aspenate of adenosine, its method of preparation from adenosine, and its use for the preparation of medicines for the treatment of fibrosive hepatic diseases and pharmaceut composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114501

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SELGEVITY CO., LTD.

Free format text: FORMER OWNER: BIOLOGICAL PHARMACY

Effective date: 20100408

Owner name: MAX INTERNATIONAL CO., LTD.

Free format text: FORMER OWNER: SELGEVITY CO., LTD.

Effective date: 20100408

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: CALIFORNIA, U.S.A. TO: UTAH STATE, USA

TA01 Transfer of patent application right

Effective date of registration: 20100408

Address after: Utah, USA

Applicant after: Max International Ltd.

Address before: American California

Applicant before: Sal Jerve Te Ltd.

Effective date of registration: 20100408

Address after: American California

Applicant after: Sal Jerve Te Ltd.

Address before: American California

Applicant before: Max International, LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1114501

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20071024

C20 Patent right or utility model deemed to be abandoned or is abandoned